ArticleHaematologica2014
EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
Open access · goldAbstract readLetter
In one paragraph
Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- BifurcatoR: A Framework for Revealing Clinically Actionable Signal in Variance Masquerading as Noise.bioRxiv : the preprint server for biology · 2025Article
- Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.International journal of hematology · 2025Article
- HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia.Leukemia · 2025Article
- Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.Haematologica · 2023Article
- Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.Blood advances · 2022Article
- The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- HighFrontiers in oncology · 2021Article
- Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.Blood advances · 2020Article
- EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.Haematologica · 2020Article
- Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway.Journal of Cancer · 2020Article
- Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.Blood advances · 2019Article
- Prognostic Value ofIranian journal of pathology · 2018Review
- Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.Journal of translational medicine · 2017Article
- Purification of leukemic blast cells from blood smears using laser microdissection.International journal of hematology · 2017Article
- [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR.Bone marrow transplantation · 2016Article
- Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Review
- The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.Haematologica · 2015Article
- The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.Haematologica · 2015Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 14 institutions in 1 country.
Hidemasa MatsuoDepartment of Human Health Sciences, Kyoto University, Japan.
Mio KajiharaDepartment of Human Health Sciences, Kyoto University, Japan.
Daisuke TomizawaDepartment of Pediatrics, Tokyo Medical and Dental University (TMDU), Japan.
Tomoyuki WatanabeDepartment of Nutritional Science, Aichi Gakuin University, Nisshin, Japan.
Akiko Moriya SaitoClinical Research Center, National Hospital Organization Nagoya Medical Center, Japan.
Junichiro FujimotoEpidemiology and Clinical Research Center for Children's Cancer, National Center for Child Health and Development, Tokyo, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Japan.
Kumi KodamaDepartment of Human Health Sciences, Kyoto University, Japan.
Mayu TokumasuDepartment of Pediatrics, Kyoto University, Japan.
Hiroshi ItohDepartment of Human Health Sciences, Kyoto University, Japan.
Hideki NakayamaDepartment of Pediatrics, National Hospital Organization Fukuoka-Higashi Medical Center, Koga, Japan.
Akitoshi KinoshitaDepartment of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan.
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
Akio TawaDepartment of Pediatrics, National Hospital Organization Osaka National Hospital, Japan.
Tomohiko TakiDepartment of Molecular Diagnostics and Therapeutics, Kyoto Prefectural University of Medicine, Japan.
Norio ShibaDepartment of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan.
Kentaro OhkiDepartment of Hematology and Oncology, Gunma Children's Medical Center, Shibukawa, Japan.
Yasuhide HayashiDepartment of Hematology and Oncology, Gunma Children's Medical Center, Shibukawa, Japan.
Yuka YamashitaDepartment of Pediatrics, National Hospital Organization Nagoya Medical Center, Japan.
Akira ShimadaDepartment of Pediatrics, Okayama University Hospitaland, Japan.
Shiro TanakaDepartment of Pharmacoepidemiology, Kyoto University, Japan.
Souichi AdachiDepartment of Human Health Sciences, Kyoto University, Japan adachiso@kuhp.kyoto-u.ac.jp.
Kyoto University · JPGunma Children's Medical Center · JPNagoya Medical Center · JPAichi Gakuin University · JPFukuoka Higashi Medical Center · JPGunma University · JPKyoto Prefectural University of Medicine · JPNational Center For Child Health and Development · JPNational Hospital Organization · JPOkayama University Hospital · JPOsaka National Hospital · JPShiga University of Medical Science · JPSt. Marianna University School of Medicine · JPTokyo Medical and Dental University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene ExpressionGene RearrangementDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseHumansLeukemia, Myeloid, AcuteMDS1 and EVI1 Complex Locus ProteinMyeloid-Lymphoid Leukemia ProteinPrognosisProto-OncogenesTranscription FactorsTranslocation, GeneticDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseKMT2A protein, humanMDS1 and EVI1 Complex Locus ProteinMECOM protein, humanMyeloid-Lymphoid Leukemia ProteinTranscription Factorsacute myeloid leukemiaEVI1MLLpediatricsprognostic factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.